Publications 2023

Bach-Gansmo T, Hodt A, Schjesvold FH, Gude E, Wien TN (2023)
Bone scintigraphy reduces the need for biopsy in suspected cardiac amyloidosis
Tidsskr Nor Laegeforen, 143 (9)
DOI 10.4045/tidsskr.22.0644, PubMed 37341415

Groen K, Schjesvold FH, van der Holt B, Levin MD, Seefat MR, Hansson M, Leys MBL, Regelink JC, Waage A, Szatkowski D, Axelsson P, Hieu Do T, Svirskaite A, van der Spek E, Haukas E, Knut-Bojanowska D, Ypma PF, Blimark CH, Mellqvist UH, van de Donk NWCJ, Sonneveld P, Klostergaard A, Vangsted AJ, Abildgaard N, Zweegman S (2023)
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
Hemasphere, 7 (9), e940
DOI 10.1097/HS9.0000000000000940, PubMed 37663673

Gundesen MT, Asmussen JT, Schjesvold F, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Teodorescu EM, Jensen BA, Slørdahl TS, Nahi H, Waage A, Abildgaard N, Lund T, Nordic Myeloma Study Group (2023)
Potential value of pre-planned imaging of bone disease in multiple myeloma
Blood Cancer J, 13 (1), 105
DOI 10.1038/s41408-023-00880-0, PubMed 37419876

Köhn-Luque A, Myklebust EM, Tadele DS, Giliberto M, Schmiester L, Noory J, Harivel E, Arsenteva P, Mumenthaler SM, Schjesvold F, Taskén K, Enserink JM, Leder K, Frigessi A, Foo J (2023)
Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data
Cell Rep Methods, 3 (3), 100417
DOI 10.1016/j.crmeth.2023.100417, PubMed 37056380

Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M et al. (2023)
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Lancet Oncol, 24 (6), e255-e269
DOI 10.1016/S1470-2045(23)00159-6, PubMed 37269857

Nørgaard JN, Abildgaard N, Lysén A, Tsykunova G, Vangsted AJ, João C, Remen N, Nielsen LK, Osnes L, Stokke C, Connelly JP, Revheim MR, Nordic Myeloma Study Group (NMSG), Schjesvold F (2023)
Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation
Leukemia (in press)
DOI 10.1038/s41375-023-01998-7, PubMed 37568010

Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, Choeurng V, Li J, Hendricks R, Ruppert SM, Sumiyoshi T, Miller K, Cho E, Schjesvold F (2023)
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Clin Hematol Int, 5 (1), 43-51
DOI 10.1007/s44228-022-00023-5, PubMed 36656461

Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV (2023)
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica (in press)
DOI 10.3324/haematol.2023.283509, PubMed 37646660

Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H (2023)
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Leukemia, 37 (6), 1349-1360
DOI 10.1038/s41375-023-01883-3, PubMed 37024520

Sonneveld P, Richardson PG, Ludwig H, Dimopoulos MA, Schjesvold FH, Hájek R, Abdulhaq H, Thuresson M, Norin S, Bakker NA, Mateos MV (2023)
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Clin Lymphoma Myeloma Leuk, 23 (9), 687-696
DOI 10.1016/j.clml.2023.05.004, PubMed 37355418

Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk NWCJ, Ntanasis-Stathopoulos I, Vangsted AJ, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hajek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos MA, Sonneveld P, Ludwig H (2023)
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Leukemia, 37 (6), 1175-1185
DOI 10.1038/s41375-023-01920-1, PubMed 37142661

van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Grasso M, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro M et al. (2023)
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
Lancet Oncol (in press)
DOI 10.1016/S1470-2045(23)00405-9, PubMed 37717583

Publications 2022

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee ESMO Guidelines Committee. Electronic address: guidelines@ehaweb.org (2022)
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
Ann Oncol, 33 (9), 988
DOI 10.1016/j.annonc.2022.05.004, PubMed 35810138

Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S (2022)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Blood Cancer J, 12 (1), 9
DOI 10.1038/s41408-021-00593-2, PubMed 35075109

Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold F, Munthe LA, Taskén K (2022)
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
Mol Oncol, 16 (6), 1241-1258
DOI 10.1002/1878-0261.13191, PubMed 35148457

Gundesen MT, Asmussen JT, Haukås E, Schubert M, Abildgaard N, Schjesvold F, Lund T (2022)
A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma
Eur J Haematol, 108 (5), 423-429
DOI 10.1111/ejh.13749, PubMed 35113466

Janssens R, Lang T, Vallejo A, Galinsky J, Morgan K, Plate A, De Ronne C, Verschueren M, Schoefs E, Vanhellemont A, Delforge M, Schjesvold F, Cabezudo E, Vandebroek M, Stevens H, Simoens S, Huys I (2022)
What matters most to patients with multiple myeloma? A Pan-European patient preference study
Front Oncol, 12, 1027353
DOI 10.3389/fonc.2022.1027353, PubMed 36523996

Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min, Ocio EM, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson PG (2022)
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Ann Hematol, 101 (10), 2123-2137
DOI 10.1007/s00277-022-04917-5, PubMed 35943588

Ocio EM, Nadeem O, Schjesvold F, Gay F, Touzeau C, Dimopoulos MA, Richardson PG, Mateos MV (2022)
Melflufen for the treatment of multiple myeloma
Expert Rev Clin Pharmacol, 15 (4), 371-382
DOI 10.1080/17512433.2022.2075847, PubMed 35723075

Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC (2022)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Lancet Oncol, 23 (3), 416-427
DOI 10.1016/S1470-2045(22)00019-5, PubMed 35151415

Schjesvold F, Paiva B, Ribrag V, Rodriguez-Otero P, San-Miguel JF, Robak P, Hansson M, Onishi M, Hamidi H, Malhi V, Dail M, Javery A, Ku G, Raab MS (2022)
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Clin Lymphoma Myeloma Leuk, 23 (1), e59-e70
DOI 10.1016/j.clml.2022.10.006, PubMed 36450626

Schjesvold F, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, Van de Velde H, Bensfia S, Bringhen S (2022)
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Haematologica, 107 (3), 774-775
DOI 10.3324/haematol.2021.279160, PubMed 35229573

Schjesvold FH, Bakker NA, Sonneveld P (2022)
Melflufen in multiple myeloma: the conclusion matters - Authors' reply
Lancet Haematol, 9 (4), e244-e245
DOI 10.1016/S2352-3026(22)00071-0, PubMed 35358436

Schjesvold FH, Bakker NA, Sonneveld P (2022)
Authors' reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
Transl Oncol, 25, 101528
DOI 10.1016/j.tranon.2022.101528, PubMed 36087383

Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R et al. (2022)
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Lancet Haematol, 9 (2), e98-e110
DOI 10.1016/S2352-3026(21)00381-1, PubMed 35032434

Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N et al. (2022)
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
BMC Cancer, 22 (1), 147
DOI 10.1186/s12885-022-09184-1, PubMed 35123422

Stokke C, Nørgaard JN, Feiring Phillips H, Sherwani A, Nuruddin S, Connelly J, Schjesvold F, Revheim ME (2022)
Comparison of [¹⁸F]fluciclovine and [¹⁸F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
Mol Imaging Biol, 24 (5), 842-851
DOI 10.1007/s11307-022-01734-0, PubMed 35501622

Publications 2021

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2021)
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Hemasphere, 5 (2), e528
DOI 10.1097/HS9.0000000000000528, PubMed 33554050

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee ESMO Guidelines Committee. Electronic address: guidelines@ehaweb.org (2021)
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
Ann Oncol, 33 (1), 117
DOI 10.1016/j.annonc.2021.10.001, PubMed 34857439

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2021)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^†
Ann Oncol, 32 (3), 309-322
DOI 10.1016/j.annonc.2020.11.014, PubMed 33549387

Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M et al. (2021)
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer J, 11 (12), 192
DOI 10.1038/s41408-021-00587-0, PubMed 34857730

Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frølund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N (2021)
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
Eur J Haematol, 108 (1), 34-44
DOI 10.1111/ejh.13709, PubMed 34536308

Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2021)
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 100 (1), 297-302
DOI 10.1007/s00277-020-04302-0, PubMed 33106909

Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC, Pauff JM, Kumar S (2021)
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Am J Hematol, 96 (4), 418-427
DOI 10.1002/ajh.26083, PubMed 33368455

Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H et al. (2021)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Lancet Haematol, 8 (12), e934-e946
DOI 10.1016/S2352-3026(21)00278-7, PubMed 34756169

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C et al. (2021)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Lancet Oncol, 22 (3), e105-e118
DOI 10.1016/S1470-2045(20)30756-7, PubMed 33662288

Richardson PG, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F, Le-Guennec S, Macé S, Dimopoulos MA (2021)
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study
Future Oncol, 17 (34), 4797-4812
DOI 10.2217/fon-2021-0568, PubMed 34521277

Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R et al. (2021)
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Eur J Haematol, 108 (1), 73-83
DOI 10.1111/ejh.13706, PubMed 34496096

Schjesvold F, Bringhen S, G Richardson P, Perrot A, Leleu X, Moreau P, A Dimopoulos M, Hulin C, Tekle C, Foster MC, Poole EM, van de Velde H, Facon T (2021)
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Am J Hematol, 96 (11), E423-E427
DOI 10.1002/ajh.26319, PubMed 34383345

Schjesvold F, Oriol A (2021)
Current and Novel Alkylators in Multiple Myeloma
Cancers (Basel), 13 (10)
DOI 10.3390/cancers13102465, PubMed 34070213

Schjesvold FH, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, van de Velde H, Bensfia S, Bringhen S (2021)
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Haematologica, 106 (4), 1182-1187
DOI 10.3324/haematol.2020.253450, PubMed 32586908

Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N, Bone Working Group of the International Myeloma Working Group (2021)
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
Lancet Oncol, 22 (3), e119-e130
DOI 10.1016/S1470-2045(20)30559-3, PubMed 33545067

Tjonnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
Monoclonal gammopathy of clinical importance
Tidsskr. Nor. Laegeforen., 141 (13), 1276-1280

Tjønnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
[Monoclonal gammopathy of clinical importance]
Tidsskr Nor Laegeforen, 141 (2021-13)
DOI 10.4045/tidsskr.20.0981, PubMed 34596996

Walladbegi J, Henriksson R, Tavelin B, Svanberg A, Larfors G, Jädersten M, Schjesvold F, Mahdi A, Garming Legert K, Peterson DE, Jontell M (2021)
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
Bone Marrow Transplant, 57 (2), 191-197
DOI 10.1038/s41409-021-01512-6, PubMed 34728786

Publications 2020

Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2020)
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 99 (8), 1793-1804
DOI 10.1007/s00277-020-04149-5, PubMed 32613281

Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF et al. (2020)
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Lancet Oncol, 22 (1), 142-154
DOI 10.1016/S1470-2045(20)30680-X, PubMed 33301738

Oriol A, Larocca A, Leleu X, Hajek R, Hassoun H, Rodríguez-Otero P, Paner A, Schjesvold FH, Gullbo J, Richardson PG (2020)
Melflufen for relapsed and refractory multiple myeloma
Expert Opin Investig Drugs, 29 (10), 1069-1078
DOI 10.1080/13543784.2020.1808884, PubMed 32924646

Schjesvold F (2020)
Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019
Eur J Haematol, 105 (4), 434-448
DOI 10.1111/ejh.13464, PubMed 32557833

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos M (2020)
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
Eur J Haematol, 104 (5), 443-458
DOI 10.1111/ejh.13379, PubMed 31880006

Schjesvold F, Robak P, Pour L, Aschan J, Sonneveld P (2020)
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma
Future Oncol, 16 (11), 631-641
DOI 10.2217/fon-2020-0024, PubMed 32141766

Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B et al. (2020)
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Haematologica, 105 (12), 2879-2882
DOI 10.3324/haematol.2019.240374, PubMed 33256392

Publications 2019

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC, ICARIA-MM study group (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Lancet, 394 (10214), 2096-2107
DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H et al. (2019)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Lancet Oncol, 20 (6), e302-e312
DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P et al. (2019)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e459-e469
DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687

Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M et al. (2019)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Lancet Oncol, 20 (6), 781-794
DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405

Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J, KEYNOTE-185 Investigators (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e448-e458
DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689

Publications 2018

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R et al. (2018)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Lancet, 393 (10168), 253-264
DOI 10.1016/S0140-6736(18)33003-4, PubMed 30545780

Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18 (1), 801
DOI 10.1186/s12885-018-4722-x, PubMed 30089450

Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Schjesvold FH, Tjønnfjord GE, Munthe LA, Tasken K (2018)
In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
Blood, 132, 4676
DOI 10.1182/blood-2018-99-110357, PublikaID 304

Thimiri Govinda Raj DB, Giliberto M, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold FH, Munthe LA, Tasken K (2018)
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
DOI 10.1182/blood-2018-99-110669, PublikaID 303

Publications 2017

Schjesvold FH (2017)
[Not Available]
Tidsskr Nor Laegeforen, 137 (1), 58
DOI 10.4045/tidsskr.16.0963, PubMed 28073239

Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA (2017)
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
Leukemia, 31 (10), 2114-2121
DOI 10.1038/leu.2017.69, PubMed 28232741

Publications 2016

Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B (2015)
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
Cancer Res, 75 (16), 3268-78
DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231

Publications 2014

Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol, 5, 174
DOI 10.3389/fimmu.2014.00174, PubMed 24782871

Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B (2014)
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
Eur J Immunol, 44 (9), 2625-37
DOI 10.1002/eji.201444659, PubMed 24846412

Publications 2013

Schjesvold F, Wiencke K, Tjønnfjord GE (2013)
[Investigation of anemia]
Tidsskr Nor Laegeforen, 133 (6), 610
DOI 10.4045/tidsskr.13.0256, PubMed 23552139

Schjesvold FH (2013)
[Investigation of amyloidosis]
Tidsskr Nor Laegeforen, 133 (3), 266
DOI 10.4045/tidsskr.13.0044, PubMed 23381155

Publications 2012

Tazmini K, Bakken HN, Schjesvold FH (2012)
A woman in her seventies with reduced general condition, dyspnoea and generalised pain
Tidsskr Nor Laegeforen, 132 (17), 1969-72
DOI 10.4045/tidsskr.11.0608, PubMed 23007363

Publications 2009

Schjesvold FH (2009)
[Erythrocytosis as a problem]
Tidsskr Nor Laegeforen, 129 (22), 2387; author reply 2387
DOI 10.4045/tidsskr.09.1196, PubMed 19935946

Publications 2008

Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L (2008)
[High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
Tidsskr Nor Laegeforen, 128 (12), 1392-6
PubMed 18552900